Fredun Pharmaceuticals shines on getting nod to manufacture Xenografts
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Fredun Pharmaceuticals is currently trading at Rs. 955.00, up by 45.05 points or 4.95% from its previous closing of Rs. 909.95 on the BSE.
The scrip opened at Rs. 929.95 and has touched a high and low of Rs. 955.00 and Rs. 929.95 respectively. So far 1852 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 1140.00 on 31-Jan-2022 and a 52 week low of Rs. 351.20 on 23-Aug-2021.
Last one week high and low of the scrip stood at Rs. 955.00 and Rs. 778.00 respectively. The current market cap of the company is Rs. 422.87 crore.
The promoters holding in the company stood at 51.27%, while Institutions and Non-Institutions held 1.69% and 47.04% respectively.
Fredun Pharmaceuticals has received the approval for manufacturing Xenografts for various Dental and Orthopaedic surgical appliances from Central Drugs Standard Control Organisation (COSCO), India. With this, the Company aims to penetrate the Dental fraternity across India. With many doctors now using grafts, company expanding product portfolio with this new addition to take advantage of the growing opportunity.
Fredun Pharmaceuticals was established to produce drugs of international standards at affordable prices. The company produces anti -bacterial, anti-malarial, anti-diabetic tablets, capsules and dry syrups.
